[Intravesical instillation of combined adriamycin and verapamil in preventing recurrence of superficial bladder tumor]

Zhonghua Wai Ke Za Zhi. 1993 Jun;31(6):330-2.
[Article in Chinese]

Abstract

Multidrug-resistance of the tumor cells is the main cause for failure of chemotherapy. Such resistance is correlated to P-glycoprotein 170, which can pump the chemotherapeutic agent out of the tumor cells. This action could be reversed by verapamil through competition for closely related binding sites on P-glycoprotein. Twenty-four postoperative cases of superficial bladder tumors were treated by intravesical instillation of combined adriamycin and verapamil, and they were followed up for 17-35 months (average 24.5 months). Two cases (8.7%) had recurrence. NO marked toxicity and side-effects were observed. Verapamil working as a drug-resistance reversing agent might be used in some other tumors not sensitive to chemotherapy.

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Administration, Intravesical
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Carrier Proteins / drug effects
  • Doxorubicin / administration & dosage
  • Drug Resistance
  • Female
  • Humans
  • Male
  • Membrane Glycoproteins / drug effects
  • Middle Aged
  • Neoplasm Proteins / drug effects
  • Neoplasm Recurrence, Local / prevention & control*
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / surgery
  • Verapamil / administration & dosage

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Carrier Proteins
  • Membrane Glycoproteins
  • Neoplasm Proteins
  • Doxorubicin
  • Verapamil